ClinicalTrials.gg
Active, not recruitingNCT06169722Updated Sep 26, 2025

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

A Phase 1/2 interventional study of TDI01 suspension in GVHD, Chronic, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Planned enrollment
18th of 42
60 · median 50
Started
2024
with 4 others
Phase 1/2
5 of 52
1 open now
Primary completion
2026-02
later than 6 of 24 live
Registered
30th of 52
by date

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 18th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 6 of the 24 other live ones, and was the 30th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

  1. Phase Ib study stage:

    Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics

  2. Phase II study stage:

Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety

Read the detailed description
  1. Phase Ib study stage:

    Primary objective: To evaluate the efficacy and safety of TDI01 suspension in treating patients with moderate or severe Chronic Graft-Versus-Host Disease after failure of at least 1 and not more than 5 lines of systemic therapy Secondary objectives: To evaluate the population pharmacokinetic characteristics of TDI01 suspension in treating patients with moderate or severe Chronic Graft-Versus-Host Disease after failure of at least 1 and not more than 5 lines of systemic therapy.

  2. Phase II study stage:

Primary objective: To evaluate the efficacy of TDI01 suspension in treating patients with moderate or severe Chronic Graft-Versus-Host Disease after failure of at least 1 and not more than 5 lines of systemic therapy Secondary objectives: To evaluate the safety of TDI01 suspension in treating patients withmoderate or severe Chronic Graft-Versus-Host Disease after failure of at least 1 and not more than 5 lines of systemic therapy as well as the population pharmacokinetic characteristics of TDI01 suspension in treating these patients.

03

Conditions studied

  • GVHD, Chronic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this study, sign the form, and have good compliance;
  2. Subjects are aged between 18 and 75 years old, regardless of gender;
  3. Within 7 days prior to the first dose, the (ECOG) performance status score is 0-2;
  4. Subjects are expected to survive for more than 6 months;
  5. Subjects have previously received hematopoietic stem cell transplantation;
  6. Subjects have received systemic treatment for cGVHD of ≤5 lines but ≥1 line before;
  7. Diagnosed with moderate to severe cGVHD based on NIH criteria, defined as follows:

    Moderate cGVHD: involvement of ≥3 organs with organ scores of 1 point, or involvement of ≥1 organ (excluding the lung) with organ scores of 2 points, or involvement of the lung with organ scores of 1 point; Severe cGVHD: involvement of ≥1 organ (excluding the lung) with organ scores of 3 points, or involvement of the lung with organ scores of 2 points or higher.

  8. Diagnosed with -resistant/dependent cGVHD based on NIH criteria, meeting any of the following conditions:

Subjects who have received at least 2 lines but no more than 5 lines in the past are required to have stable systemic therapy (such as corticosteroids, calcineurin inhibitors, sirolimus, mycophenolate mofetil (MMF), methotrexate, and extracorporeal phototherapy (ECP)) for at least two weeks prior to screening.

Subjects who have only received glucocorticoid combined or not combined with calcineurin inhibitors in the past,Diagnosed as glucocorticoid resistant/dependent cGVHD according to NIH criteria, meeting any of the following conditions:

Subjects receiving ≥1 mg/kg prednisone (or equivalent dose of glucocorticoids) for at least 1 week but still have disease progression (glucocorticoid-resistant cGVHD); Subjects receiving ≥0.5 mg/kg/day or ≥1 mg/kg every other day prednisone (or equivalent dose of glucocorticoids) for at least 4 weeks but still have persistent disease symptoms without improvement ( glucocorticoid-resistant cGVHD); Subjects who have failed to reduce the glucocorticoid dose twice and have increased the prednisone (or equivalent dose of glucocorticoids) to >0.25 mg/kg/day (glucocorticoid-dependent cGVHD).

Exclusion criteria

Exclusion Criteria:

  1. The presence of recurrence of the primary disease, or having received treatment for recurrence of the primary disease after (Hematopoietic stem cell transplant), or the possible need for rapid drug withdrawal as emergency treatment for early recurrence of malignant tumors; or the presence of post-transplant lymphoproliferative disorders.
  2. Patients with acute and those with overlapping chronic GVHD.
  3. Patients who have suffered from other malignant tumors except for the transplanted tumor within the past 3 years, with the exception of locally curable cancers (i.e., those that have already been cured), such as basal cell carcinoma or squamous cell carcinoma of the skin, cervical or breast carcinoma in situ, or superficial bladder cancer.
  4. Unable to swallow medication normally, or with gastrointestinal dysfunction, or deemed by the investigator to potentially affect drug absorption.
  5. The presence of active infection, including bacterial, fungal, viral (such as CMV(cytomegalovirus), EBV(epstein-barr virus), etc.) or parasitic infections that require treatment.
  6. Poor diabetes control (fasting blood glucose (FBG) > 10 mmol/L).
  7. Inadequate blood pressure control (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100 mmHg).
  8. History of myocardial infarction within 6 months prior to planned initiation of TDI01 treatment, or arrhythmia (CTC AE(adverse event) grade 2 or higher, including ≥450ms (men), QTcF ≥470ms (women)) and congestive heart failure grade ≥2 ( (NYHA) classification).
  9. At the time of screening, (FEV1) ≤ 39% or NIH pulmonary symptom score of 3.
  10. Received systemic treatment for cGVHD within 14 days prior to enrollment; if the dose/regimen of systemic treatment has been stable for at least 2 weeks prior to screening (, calcineurin inhibitors, sirolimus, mycophenolate mofetil (MMF), methotrexate, and extracorporeal photopheresis (ECP)), it is allowed.
  11. Patients receiving treatment with Ibrutinib or Ruxolitinib within the past 28 days prior to the first administration of the study drug (except those who have completed prior to the first administration of the study drug) are excluded from participation in the study.
  12. Patients who participated in other drug or device clinical trials within 4 weeks prior to the screening visit (or 5 half-lives, whichever is longer).
  13. Patients receiving treatment with Warfarin or any other coumarin derivative anticoagulant, or patients with a bleeding tendency or coagulation disorder.
  14. Patients with positive and/or HBcAb and positive HBV-DNA (HBV-DNA negative patients are eligible); patients with positive (hepatitis C virus) antibody and HCV-RNA copy number above the lower limit of detection. Note: Eligible patients with positive hepatitis B surface antigen or hepatitis B core antibody, and patients with hepatitis C, require continuous antiviral therapy to prevent virus activation.
  15. Patients with positive antibody.
  16. Patients who have previously received treatment with a ROCK2 inhibitor.
  17. Patients with a known history of severe allergic reactions to the study drug or its major ingredients.
  18. Pregnant or breastfeeding women.
  19. Patients with known alcohol or drug dependence.
  20. Any other reason that the investigator believes may prevent a patient from participating in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    200mg

    200mg oral once a day

    Drug: TDI01 suspension

  • Active comparator
    400mg

    400mg oral once a day

    Drug: TDI01 suspension

  • Active comparator
    200mg or 400mg

    200mg or 400mg oral once a day

    Drug: TDI01 suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib study stage:The best overall response rate (BORR)

    The best overall response rate (BORR) at 24 weeks.

    Time frame: 24 weeks.

  2. Phase Ib study stage:adverse events

    The incidence of adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and treatment-related adverse events (TRAEs).

    Time frame: 24 weeks.

  3. Phase II study stage:The best overall response rate (BORR)

    The best overall response rate (BORR) at 24 weeks.

    Time frame: 24 weeks.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 24 months after the start.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Feb 6, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Aug 2027
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06169722
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Feb 6, 2024
Primary completion
Feb 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TDI01

Start the discussion